about
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirOptimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 studyInfluence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSAssociation of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroOnce daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.Class-specific relative genetic contribution for key antiretroviral drugs.Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.Predicting intestinal absorption of raltegravir using a population-based ADME simulation.CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter.Validation of Computational Approaches for Antiretroviral Dose OptimizationSimulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles.Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.Divalent metals and pH alter raltegravir disposition in vitro.Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.Raltegravir penetration in seminal plasma of healthy volunteers.Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma.Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
P50
Q34309475-FA111074-4EF1-482D-826A-87403AF312E0Q34529127-325A47D0-FDA1-4A20-B992-31DBB6261F79Q34571360-09E8EE0B-8FF1-48C0-8734-2B38422B0A92Q34975110-F063BB64-F33D-4F7E-85D9-5854838A612AQ35005018-D6DF87E1-980D-4EBD-AF25-70DB8AA1C7E8Q35668556-71C8F1D8-D4AF-4E4C-ABEE-826B555367A5Q35806474-05B70DD8-7EE0-46BB-8642-753ED035F3F8Q36087985-368CADE4-B8CB-4C90-AA5A-DC46109486D9Q36482890-1066236E-5677-4D7D-B582-DF0EACBC24F2Q36708715-FFE15596-71DC-429F-9DB9-E2F4B7AE0197Q36903895-F9423BA0-099A-4C56-9D7B-82CA1B1EE942Q37263486-F2CA344E-3073-4685-A928-7415176B9354Q37968986-9D4DF7B4-66C0-47DD-AD9D-AD68116CB3E0Q38420688-F3BA7F9B-7FBF-42FA-973B-A52A486F0DFDQ38858861-32068605-4FA7-4E14-BE07-B90001EF8CE1Q38980007-FF66A8B2-99E7-4BEE-8B48-BC6842835545Q39221388-D6E61F89-A827-4413-AC1E-C254572FB912Q39273607-A03B10D2-B7BF-4FA8-9E9B-3ACBFAAB7138Q39273613-C5BBBCAF-061A-45D8-93DB-F36792893BD7Q39321219-00DCC3B7-13FD-437F-A4A4-AD9A12B311A5Q39489002-371B130C-D32A-4DB4-88A4-165121126F65Q39863986-4C86B9D3-C61B-4890-BFD4-E2B371CA39FEQ40162850-43A36ACA-870C-4C28-9DD5-0F40B1AC2DFDQ40563147-E45D0EE8-9B9F-42C1-9048-2325E0EE7ED6Q41108275-E0A01CC3-E583-468F-8387-FB8914A4220AQ41326094-15A3D6D1-F305-4B75-8C29-E898BD834960Q41916356-CAC28702-D96D-4631-9B63-458162DB2E36Q42189797-EDC1B2C0-3700-45D6-8BAC-3131B34CC30DQ42283464-DCAB0DF6-2688-4915-A118-41FE4CB401C1Q42286670-7DAE2129-2DE4-46D9-9E4E-F4EF379A825CQ42760176-5F14FBDA-B065-45D1-A80A-E0DB940742FFQ42769995-45B443D4-6954-4653-932B-781364679BB8Q43040290-0A347C89-432D-4839-99D9-3F94087C0EB6Q43047332-B28F2848-9AEE-42AB-98AC-E0B575300741Q43081850-3FCB46D9-DBF4-43A7-BD52-BE1D91EFC9BEQ43124511-58CFC66D-0AE4-46D7-853E-528FB0A51E70Q43126068-8ED59C4A-F3BE-437E-B49E-6C64989C2266Q43205315-31E48B66-3F1F-4EFE-A95A-8BA96E422AE9Q43245950-A326CB6C-3D47-4D43-AFF1-4517BB44E685Q43954421-C6D8A87A-25AF-47C4-ACAE-2A4CC68EC764
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Siccardi
@ast
Marco Siccardi
@en
Marco Siccardi
@es
Marco Siccardi
@nl
Marco Siccardi
@sl
type
label
Marco Siccardi
@ast
Marco Siccardi
@en
Marco Siccardi
@es
Marco Siccardi
@nl
Marco Siccardi
@sl
prefLabel
Marco Siccardi
@ast
Marco Siccardi
@en
Marco Siccardi
@es
Marco Siccardi
@nl
Marco Siccardi
@sl
P106
P1153
13007436000
P21
P31
P496
0000-0002-3539-7867